Rhythm Pharmaceuticals (RYTM) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mail
Get Alerts RYTM Hot Sheet
Join SI Premium – FREE
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q4 EPS of ($0.72), $0.02 better than the analyst estimate of ($0.74). Revenue for the quarter came in at $41.83 million versus the consensus estimate of $36.04 million.
For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IREN Limited (IREN) call put ratio 2.6 calls to 1 put as share price up 7.7%
- SpaceX shares continue higher following Anthropic's $120.5bn AI deal
- Philadelphia Shooting Victim Lawyer David P. Thiruselvam Offers Civil Consultations for Gun Violence Survivors
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
